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Abstract. To the best of our knowledge, stomach antral endo-
crine cells have not previously been investigated in patients 
with irritable bowel syndrome (IBS). Thus, in the present study, 
76 patients with IBS were examined (designated as IBS-total). 
Diarrhoea was the predominant symptom in 26 of these patients 
(IBS-D), while in 21 patients, the predominant symptoms were 
both diarrhoea and constipation (IBS-M) and in 29 patients the 
predominant symptom was constipation (IBS-C). Forty-three 
healthy subjects were enrolled as the controls. Stomach antral 
biopsy samples obtained from all of the subjects were immunos-
tained using the avidin-biotin-complex method for serotonin, 
gastrin, somatostatin and serotonin transporter (SERT). The 
immunopositive cell densities and immunoreactivity intensi-
ties were determined by computer-aided image analysis. The 
density of the serotonin-immunoreactive cells was significantly 
decreased in the IBS-M patients and increased in the IBS-C 
patients relative to the controls. The immunoreactivity intensity 
did not differ significantly between the controls and IBS-total. 
The density of the gastrin-immunoreactive cells was signifi-
cantly greater in the IBS-D, IBS-M and IBS-C patients than 
in the controls. The immunoreactivity intensity of gastrin was 
significantly greater in the IBS-D patients than in the controls. 
The density of the somatostatin-immunoreactive cells cells was 
significantly lower in the IBS-total, IBS-D, IBS-M and IBS-C 
patients than in the controls. The immunoreactivity intensities 
of both somatostatin and SERT did not differ significantly 
between the controls and IBS-total. The increase in gastrin 
cell density and the decrease in somatostatin cell density in all 
IBS subtypes may cause high levels of gastric secretion, which 
may in turn contribute to the high incidence of dyspepsia and 
gastro-oesophageal reflux observed in patients with IBS.
Introduction
The gastrointestinal tract contains several types of endocrine 
cells that control and regulate a number of important functions 
of the gastrointestinal tract, enabling it to perform its main 
task, the digestion and absorption of ingested nutrients (1-4). 
These cells are dispersed among the epithelial cells of the 
mucosa and have specialised microvilli that project into the 
lumen and function as sensors, responding to luminal stimuli, 
particularly nutrients, by releasing hormones that target 
other parts of the digestive system (5-14). There are at least 
15 different populations of these cells in the gastrointestinal 
tract that interact in an integrated manner with each other, 
with the enteric nervous system, and with afferent and efferent 
nerve fibres of the central nervous system, in particular the 
autonomic nervous system (2,4).
Irritable bowel syndrome (IBS) is a common chronic func-
tional gastrointestinal disorder that considerably reduces the 
quality of life and is an economic burden to both individual 
patients and society as a whole due to the direct costs of diag-
nostic tests and treatments, and the indirect costs of the low 
productivity of patients with IBS (4). Abnormalities of endo-
crine cells have been reported in the duodenum, ileum, colon 
and rectum of patients with IBS (15-28). However, to the best of 
our knowledge, the antral endocrine cells of the stomach have 
not been previously investigated. The antrum of the stomach 
contains 3 types of endocrine cells: serotonin, gastrin and 
somatostatin cells. Therefore, the aim of the present study was 
to determine whether there are any endocrine cell or serotonin 
transporter (SERT) abnormalities in the antrum of the stomach 
of patients with IBS.
Materials and methods
Patients and controls. Seventy-six patients with IBS, classi-
fied according to the Rome III criteria for IBS as previously 
described (29,30) were included in this study. Forty patients 
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fulfilled the Rome III criteria for functional dyspepsia as well. 
These patients comprised 62 females and 14 males with a 
mean age of 32 years (range, 18-55 years). Diarrhoea was the 
predominant symptom in 26 of these patients (IBS-D), while 
in 21 patients, the predominant symptoms were both diarrhoea 
and constipation (IBS-M) and in 29 patients, the predominant 
symptom was constipation (IBS-C). All the patients (designated 
as IBS-total) had experienced their symptoms for many years 
and were unable to associate the onset of their IBS symptoms 
with any particular event, particularly gastrointestinal infec-
tions. They underwent a complete physical examination and 
were investigated by way of blood tests to exclude inflamma-
tory, liver, endocrine or any other systemic diseases. Moreover, 
they underwent a colonoscopy with segmental biopsies, which 
revealed the presence of a normal terminal ileum, colon and 
rectum in all cases. None of these patients used proton pump 
inhibitors in the last 3 months. However, they all tried proton 
pump inhibitors for short periods of time without relief of 
symptoms.
Healthy volunteers without any gastrointestinal complaints 
were recruited as the controls through local announcements 
at Stord Hospital, Haukeland University Hospital and the 
University of Bergen, Norway, as well as in the local news-
papers. Forty-three healthy subjects were included, of whom 
15 were residents of Stord and 28 were students or hospital 
employees. They comprised 32 females and 11 males with a 
mean age of 40 years (range, 20-58 years).
The study was performed in accordance with the 
Declaration of Helsinki and was approved by the Regional 
Committee for Medical and Health Research Ethics West, 
Bergen, Norway. All subjects provided both oral and written 
consent prior to participation.
Symptoms and quality of life assessments. The patients were 
asked to complete the following questionnaires: Birmingham 
IBS symptom questionnaire, the Short-Form (SF) Nepean 
Dyspepsia Index (SF-NDI) questionnaire and the Irritable 
Bowel Syndrome Quality Of Life (IBS-QOL) questionnaire. 
The control subjects were asked to complete the SF-NDI ques-
tionnaire. The Birmingham IBS symptom score questionnaire 
is a disease-specific score used to measure the symptoms of 
patients with IBS. It has been developed to be suitable for self-
completion and has been found to be acceptable by patients. Its 
dimensions have good reliability, external validity and sensi-
tivity (31). The questionnaire comprises 11 questions based on 
the frequency of IBS-related symptoms. Each question has a 
standard response scale with the symptoms all being measured 
on a 5-point Likert scale ranging from 0 (‘none of the time’) to 
5 (‘all of the time’). There are 3 underlying dimensions: pain 
(3 items), diarrhoea (5 items) and constipation (3 items) (31). 
SF-NDI was primarily constructed and validated in patients 
with functional dyspepsia (32). Later, a Norwegian transla-
tion of the form was validated and proved to be acceptable by 
patients with IBS according to the Rome II criteria for IBS (33). 
The form is a 10-item questionnaire examining the influence of 
dyspepsia on the health domains in patients, namely tension/
anxiety, interference with daily activities, disruption to regular 
eating/drinking, knowledge towards/control over disease symp-
toms and interference with work/study, with each subscale 
containing 2 items. Each item is measured by a 5-point Likert 
scale ranging from 1 (not at all or not applicable), 2 (a little), 3 
(moderately), 4 (quite a lot) to 5 (extremely). Individual items in 
each subscale are aggregated to obtain a score range from 10 
[lowest health-related quality of life (HRQoL) score] to 50 
(highest HRQoL score) as per the original calculation formula of 
the developer. High scores indicate worse functioning or symp-
toms. The IBS-QOL questionnaire is a 34-item IBS-specific 
quality of life document concerning physical and psychosocial 
functioning as a result of IBS (34). This questionnaire includes 
a 5-point Likert response scale: not at all, slightly, moderately, 
quite a lot and extremely. IBS-QOL consists of 8 domains: 
dysphoria, interference with activity, body image, health worry, 
food avoidance, social reaction, sexual function and impact on 
relations. The IBS-QOL questionnaire has been validated in 
patients with IBS (35).
Gastroscopy, histopathology and immunohistochemistry. 
Both the patients and controls underwent a standard gastros-
copy, during which 5 biopsy samples were taken from the 
antrum from the area around the pyloric sphincter. Two biopsy 
samples were used in a rapid urease test for Helicobacter 
pylori (HelicotecUT Plus; Strong Biotech, Taipei, Taiwan). 
The remaining biopsy samples were fixed overnight in 
4% buffered paraformaldehyde, embedded in paraffin and 
cut into 5-µm-thick sections. The sections were stained with 
haematoxylin-eosin, and immunostained using the avidin-
biotin complex (ABC) method with a Vectastain ABC kit 
(Vector Laboratories, Burlingame, CA, USA). The primary 
antibodies used were monoclonal mouse anti-human serotonin 
(clone 5HT-H209, code M0758; Dako, Glostrup, Denmark), 
polyclonal rabbit anti-human gastrin-17 (code IR519; Dako), 
polyclonal rabbit anti-synthetic cyclic (1-14) somatostatin 
(code A0566; Dako) and monoclonal mouse anti-synthetic 
peptide from human SERT (code ab136607; Abcam, 
Cambridge, UK). The sections were incubated at room 
temperature for 2 h with all primary antibodies diluted to 
1:100, apart from the antibody against gastrin, which was 
supplied in a ready-to-use form. The sections were then 
washed in PBS buffer (pH 7.4) and incubated with biotinylated 
swine anti-mouse IgG (in the case of monoclonal antibodies) 
or goat anti-rabbit IgG (in the case of polyclonal antibodies), 
both diluted to 1:200, for 30 min at room temperature. After 
washing the slides in PBS buffer, the sections were incubated 
for 30 min with peroxidase-labelled ABC diluted to 1:100, and 
then immersed in 3,3'-diaminobenzidine peroxidase substrate 
(Vector Laboratories), followed by counterstaining with 
haematoxylin.
Computerised image analysis. A microscope (type BX 43; 
Olympus, Tokyo, Japan) equipped with built-in Koehler 
illumination for transmitted light, a light-intensity manager 
switch, a high-colour-reproductivity LED light source, a 
6 V/30 W halogen bulb and a DP26 Olympus camera was 
used for morphometric analysis. This microscope was linked 
to a computer with Olympus cellSens imaging software 
(version 1.7). The number of immunoreactive cells, the area 
of epithelial cells and the immunoreactivity intensity were 
measured. The number of immunoreactive cells in each field 
was counted manually by pointing and clicking the computer 
mouse, and the areas of the epithelial cells were drawn 
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manually using the computer mouse. The areas considered 
for quantification were those near to the muscularis mucosa. 
The immunoreactivity intensity in each field was measured 
using an automatic threshold setting. A x40 objective was 
used, for which each frame (field) on the monitor represented 
a tissue area of 0.035 mm2. Measurements were made in 
10 randomly selected fields for each individual. The immu-
nostained sections from the IBS patients and the controls 
were coded and mixed, and measurements were made by the 
same person (M.E.-S.), who was blind to the identity of the 
individual to whom the tissue sections belonged. The data 
from the fields were tabulated, and the cell density of the 
epithelium (in cells/mm2) and the immunoreactivity intensity 
were computed.
Statistical analysis. The gender difference and the occur-
rence of Helicobacter pylori infection between the patients 
and the controls was examined using Fisher's exact test. The 
differences in age and quality of life measured by SF-NDI 
were calculated using the Mann-Whitney non-parametric test. 
Differences between the control, IBS-total, IBS-D, IBS-M 
and IBS-C groups were calculated using the Kruskal-Wallis 
non-parametric test with the Dunn's post-test. The data are 
presented as means ± SEM values, and differences with 
P<0.05 were considered statistically significant.
Results
Patients and controls. The gender and age distributions did 
not differ significantly between the patients and the controls 
(P=0.196 and P=0.360, respectively). A total of 3 patients 
and 2 control subjects were positive for Helicobacter pylori 
infection, as revealed by both the urease test and histopatho-
logical examinations. The prevalence of Helicobacter pylori 
infection did not differ significantly between the patients and 
the controls (P=1.0). The total score of the Birmingham IBS 
symptom questionnaire was 21.5±0.7. The pain, diarrhoea and 
constipation dimensions were 7.2±0.4, 6.6±0.4 and 7.2±0.4, 
respectively. The total score of the SF-NDI questionnaire 
in the controls was 10.5±0.5 and in the IBS patients it was 
26±1.2. There was a significant difference in the reduction 
of the quality of life according to the SF-NDI questionnaire 
between the controls and patients with IBS (P<0.0001). The 
total score of the IBS-QOL questionnaire in the patients with 
IBS was 72.7±1.5.
Gastroscopy, histopathology and immunohistochemistry. The 
oesophagus, stomach and duodenum were macroscopically 
and microscopically normal in both the patients and controls. 
Immunoreactive cells were found in the stomach antrum of 
both the patients and the controls, and were either basket- or 
flask-shaped, sometimes with a long basal cytoplasmic process.
Computerised image analysis
Serotonin. The densities of the serotonin-immunoreactive 
cells were 135.0±15.0, 141.3±17.9, 163.4±18.2, 7.2±2.3 and 
302.3±36.3 cells/mm2 in the control, IBS-total, IBS-D, 
IBS-M and IBS-C groups, respectively. The density of the 
serotonin-immunoreactive cells was significantly lower in 
the IBS-M group and higher in the IBS-C group compared 
with the controls (IBS-C, P<0.05; IBS-M, P<0.01 compared 
to controls; Figs. 1 and 2). The immunoreactivity intensities 
of serotonin were 125.3±1.5, 127.1±1.3, 128.8±2.1, 122.2±0.4 
and 127.8±1.8 in the control, IBS-total, IBS-D, IBS-M and 
IBS-C groups, respectively, with no statistically significant 
differences between any of these groups (P=0.2; Figs. 1 and 2).
Gastrin. The densities of the gastrin-immunoreactive cells 
were 344.8±38.2, 567.9±38.9, 591.0±67.6, 579.1±54.7 and 
612.9±61.1 cells/mm2 in the control, IBS-total, IBS-D, IBS-M 
and IBS-C groups, respectively. The densities of gastrin-
immunoreactive cells differed significantly between the 
controls and the IBS-total and the IBS subgroups (P<0.0001). 
The density of the gastrin-immunoreactive cells differed 
significantly between the controls and the IBS-total, IBS-D, 
IBS-M and IBS-C patients (P<0.01, P<0.05, P<0.05 and P<0.01, 
respectively; Figs. 3 and 4). The immunoreactivity intensities 
of gastrin were 130.8±0.8, 134.6±1.0, 139.3±1.3, 129.7±0.9 and 
133.7±1.7 in the control, IBS-total, IBS-D, IBS-M and IBS-C 
groups, respectively, with statistically significant differences 
between all groups (P=0.0001). The gastrin immunoreactivity 
Figure 1. (A) Densities of serotonin-immunoreactive cells and (B) serotonin immunoreactivity intensities in the stomach antrum of the controls and IBS-total, 
IBS-D, IBS-M and IBS-C patients. *P<0.05, **P<0.01 vs. controls. IBS, irritable bowel syndrome; IBS-total, all 76 patients with IBS in this study; IBS-D, 
diarrhoea was the predominant symptom in 26 of these patients; IBS-M, predominant symptoms were both diarrhoea and constipation in 21 patients; IBS-C, 
predominant symptom was constipation in 29 patients.
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intensity was significantly higher in the IBS-D patients than in 
the controls (P=0.0001; Figs. 3 and 4).
Somatostatin. The densities of somatostatin-immunoreac-
tive cells were 365.6±55.9, 152.0±14.6, 131.5±18.3, 113.4±21.2 
and 207.3±30.5 cells/mm2 in the control, IBS-total, IBS-D, 
IBS-M and IBS-C groups, respectively. There was a statis-
tical difference between the controls and the IBS subgroups 
(P=002). The density of the somatostatin-immunoreactive cells 
was significantly lower in the IBS-total, IBS-D, IBS-M and 
IBS-C patients than in the controls (P<0.01, P<0.01, P<0.01 and 
P<0.05, respectively). There was no significant difference in 
somatostatin immunoreactivity intensity between the controls 
(127.1±0.9) and the IBS-total (124.8±0.5), IBS-D (125.0±0.7), 
IBS-M (125.6±0.6) and IBS-C (124.3±1.0) patients (P=0.369; 
Figs. 5 and 6).
SERT. The immunoreactivity intensities for SERT were 
132.7±1.4, 132.0±0.7, 134.5±0.8, 131.1±1.2 and 130.5±1.4 
in the control, IBS-total, IBS-D, IBS-M and IBS-C groups, 
Figure 2. Antral serotonin-immunoreactive cells in (A) a control subject, in (B) a patient with IBS-M and in (C) a patient with IBS-C. IBS, irritable bowel 
syndrome; IBS-M, predominant symptoms were both diarrhoea and constipation; IBS-C, predominant symptom was constipation.
Figure 3. (A) Densities of gastrin-immunoreactive cells and (B) gastrin immunoreactivity intensities in the stomach antrum of the controls and IBS-total, IBS-D, 
IBS-M and IBS-D patients. *P<0.05, **P<0.01, ***P< 0.0001 vs. controls. IBS, irritable bowel syndrome; IBS-total, all 76 patients with IBS in this study; IBS-D, 
diarrhoea was the predominant symptom in 26 of these patients; IBS-M, predominant symptoms were both diarrhoea and constipation in 21 patients; IBS-C, 
predominant symptom was constipation in 29 patients.
Figure 4. Gastrin-immunoreactive cells in the stomach antrum of (A) a control subject, (B) a patient with IBS-D and (C) a patient with IBS-C. The immuno-
reactivity intensity is highest in the patient with IBS-D. IBS, irritable bowel syndrome; IBS-D, diarrhoea was the predominant symptom; IBS-C, predominant 
symptom was constipation.
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respectively, with no significant differences between any of 
these groups (P=0.142; Figs. 7 and 8).
Discussion
The patients with IBS examined in this study had moderate 
symptoms. These symptoms appeared, however, to consider-
ably reduce their quality of life. Approximately 53% of these 
patients suffered from functional dyspepsia in addition to IBS.
The present study measured the density of endocrine 
cells, which are the anatomical units responsible for the 
production of hormones. Furthermore, the immunoreactivity 
intensity, which reflects the cellular hormone (secretory 
granules) content, and hence the summation of the cellular 
synthesis and release of that particular hormone was detected. 
The immunoreactivity intensity is a semi-quantative method 
measured in arbitrary units and is useful for comparing groups 
immunostained under the same conditions. Modern advances 
in the illumination used to visualise specimens on microscopes 
and in computer software have now made it possible to obtain 
reliable measurements of this parameter. The findings of the 
present study revealed abnormalities in all the endocrine cell 
types in the stomach antrum, namely the serotonin-, gastrin- 
and somatostatin-secreting endocrine cells. In patients with 
IBS, regardless of the subtype, the density of gastrin-secreting 
cells increased, while that of the somatostatin-secreting cells 
decreased.
The density of serotonin-secreting cells differed between 
the IBS subtypes. Whereas the density of serotonin-secreting 
cells was unaltered in the IBS-D patients (relative to the 
controls), it was decreased in IBS-M patients and increased 
in the IBS-C patients. Serotonin activates the submucosal 
sensory branch of the enteric nervous system, which conveys 
sensation from the gut to the central nervous system and 
stimulates the intrinsic primary afferent neurons that initiate 
peristaltic reflexes (36-39). The increased density of serotonin-
Figure 5. (A) Somatostatin-immunoreactive cell densities and (B) somatostatin immunoreactivity intensities in IBS-total, IBS-D, IBS-M and IBS-D patients. *P<0.05, 
**P<0.01 vs. controls. IBS, irritable bowel syndrome; IBS-total, all 76 patients with IBS in this study; IBS-D, diarrhoea was the predominant symptom in 26 of these 
patients; IBS-M, predominant symptoms were both diarrhoea and constipation in 21 patients; IBS-C, predominant symptom was constipation in 29 patients.
Figure 6. Stomach antral somatostatin-immunoreactive cells in (A) a control subject and in (B) a patient with IBS-C. IBS, irritable bowel syndrome; IBS-C, 
predominant symptom was constipation.
Figure 7. SERT immunoreactivity intensities in IBS-total, IBS-D, IBS-M and 
IBS-D patients. IBS, irritable bowel syndrome; IBS-total, all 76 patients with 
IBS in this study; IBS-D, diarrhoea was the predominant symptom in 26 of these 
patients; IBS-M, predominant symptoms were both diarrhoea and constipation 
in 21 patients; IBS-C, predominant symptom was constipation in 29 patients.
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secreting cells in the IBS-C patients may reflect an attempt 
to increase motility and initiate peristaltic reflexes in the 
presence of constipation. The increased serotonin levels in 
IBS-C patients may explain the nausea that these patients 
experience. However, it is difficult to ascertain why the density 
of serotonin-secreting cells decreased in the IBS-M patients, 
but not in the IBS-D patients based on a secondary effect on 
motility. Genetic abnormalities in SERT have been observed 
in patients with IBS and it has been reported that SERT levels 
are decreased in the large intestine and increased in the ileum 
of patients with IBS (20,40-46). There were no abnormalities 
in SERT immunoreactivity in the antrum of the patients with 
IBS included in the present study.
The density of gastrin-immunoreactive cells was higher 
in the patients with IBS (regardless of subtype) than in the 
controls. The increased gastrin immunoreactivity intensity 
in the IBS-D patients may be caused by either increased 
synthesis or decreased release of the hormone. On the other 
hand, the density of somatostatin-immunoreactive cells was 
lower in all the subtypes of IBS than in the healthy controls. 
Gastrin is the main hormonal stimulant of acid secretion in 
the stomach (47-51); it stimulates parietal cells both directly 
and indirectly by releasing histamine from enterochromaffin-
like cells (47,48,51,52). Somatostatin inhibits acid secretion 
directly by acting on parietal cells and indirectly by inhibiting 
histamine and gastrin secretion (47-51). The present findings 
of increased gastrin and decreased somatostatin in all IBS 
subtypes may cause a high level of gastric acid secretion, which 
may account for the high incidence of dyspepsia and gastro-
oesophageal reflux observed in patients with IBS (53-61).
In conclusion, the present study found abnormalities in all 
3 endocrine cell types in the stomach antrum of patients with 
IBS. The nature of the abnormalities in the serotonin-secreting 
cells differed between the IBS subtypes, while all IBS subtypes 
had a high density of gastrin-immunoreactive cells and a low 
density of somatostatin-immunoreactive cells. Since gastrin is 
the main stimulator and somatostatin is the principal inhibitor 
of gastric acid secretion, a high gastric secretion is to be 
expected in patients with IBS. These findings may explain the 
overlap of IBS with dyspepsia and gastro-oesophageal reflux.
IBS is considered to be a large intestinal disorder and conse-
quently the colonic and rectal endocrine cells have been the 
subjects of several studies to elucidate a possible role of these 
cells in the pathophysiology of IBS. Thus, colonic serotonin and 
PYY cell densities have been found to be low in both IBS-D and 
IBS-C patients (18). In the rectum of patients with sporadic (non-
specific) IBS, the densities of PYY and enteroglucagon cells have 
been shown to be significantly lower and those of somatostatin-
secreting cells to be significantly higher in both IBS-D and 
IBS-C patients compared to the controls, whereas the density of 
serotonin-secreting cells in these patients did not differ from that 
in the healthy controls (19,20). Rectal serotonin and PYY cell 
densities in post-infectious IBS have been reported to be elevated 
(22,24,26,62,63). Recently, however, abnormalities in the endo-
crine cells in the stomach and duodenum have been reported 
in patients with IB (15-28). The density of ghrelin cells in the 
oxyntic mucosa of the stomach has been shown to be lower in 
IBS-C and higher in IBS-D patients than in healthy controls (15). 
In the duodenum, the densities of GIP- and somatostatin-
secreting cells have been shown to be decreased in both IBS-D 
and IBS-C patients (17). The densities of duodenal secretin and 
cholecystokinin (CCK) cells are decreased in IBS-D patients but 
unaltered in IBS-C patients (17). The duodenal serotonin cells 
are not affected in both IBS-D and IBS-C patients (17). Post-
infectious IBS has been found to be associated with increased 
numbers of duodenal CCK cells but decreased numbers of 
serotonin cells (16). The present observation of abnormalities in 
the antral endocrine supports the suggestion that the endocrine 
cells are abnormal in all the segments of the gastrointestinal tract 
and IBS is a disorder that is not restricted to the large intestine. 
The present findings emphasise the role of gut endocrine cells 
in the pathophysiology of IBS. Moreover, they lend support to 
the assumption that abnormalities in gastrointestinal cells can 
explain the dysmotility, abdominal visceral hypersensitivity and 
abnormal gut secretion observed in patients with IBS (64,65).
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